COLL Q4 2020 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$76M+2.8% YoY

Gross Profit

$44M58.1% margin

Operating Income

$15M19.7% margin

Net Income

$7M9.1% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

-3.7%

Cash Flow

Operating Cash Flow

$23M

Free Cash Flow

$21M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$644M

Total Liabilities

$458M

Stockholders' Equity

$186M

Cash & Equivalents

$174M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$76M	$74M	+2.8%
Gross Profit	$44M	$25M	+76.4%
Operating Income	$15M	-$2M	+731.9%
Net Income	$7M	-$2M	+416.1%

Revenue Segments

Nucynta

$45M37%

Xtampza

$31M25%

Nucynta Ir

$29M24%

Nucynta Er

$16M13%